1997 - Fellow of the American Academy of Arts and Sciences
Stephen L. Hauser mostly deals with Multiple sclerosis, Immunology, Genetics, Allele and Internal medicine. His work carried out in the field of Multiple sclerosis brings together such families of science as Central nervous system disease, Surgery, Disease, Pathology and Myelin. His Disease research includes themes of Pathogenesis, Immune system, Natural history, Neuroscience and Pediatrics.
His Immunology study frequently draws connections between related disciplines such as Myelin basic protein. His Allele research focuses on subjects like Locus, which are linked to Genetic admixture and Age of onset. The concepts of his Internal medicine study are interwoven with issues in Placebo and Ocrelizumab.
His scientific interests lie mostly in Multiple sclerosis, Immunology, Genetics, Internal medicine and Ocrelizumab. His biological study deals with issues like Genetic association, which deal with fields such as Genome-wide association study. His work in Immune system, T cell, Antigen, Antibody and Encephalomyelitis are all subfields of Immunology research.
His biological study spans a wide range of topics, including Gastroenterology, Endocrinology, Surgery and Oncology. His work deals with themes such as Disability progression, Opera and Placebo, which intersect with Ocrelizumab. His Allele research integrates issues from Human leukocyte antigen, Major histocompatibility complex and Genotype.
Stephen L. Hauser mainly investigates Multiple sclerosis, Internal medicine, Ocrelizumab, In patient and Neutrino. His Multiple sclerosis research is classified as research in Immunology. He frequently studies issues relating to Central nervous system and Immunology.
His Internal medicine study combines topics in areas such as Gastroenterology, Oncology and Cardiology. His work in Ocrelizumab tackles topics such as Disability progression which are related to areas like Relapse rate. His Neutrino research includes elements of Universe, Astronomy and Astrophysics.
Multiple sclerosis, Internal medicine, Ocrelizumab, Expanded Disability Status Scale and Immunology are his primary areas of study. His Multiple sclerosis study integrates concerns from other disciplines, such as Cohort study, B cell, Disability progression, Magnetic resonance imaging and Disease. His work on Early disease as part of general Disease study is frequently linked to Effective management, therefore connecting diverse disciplines of science.
Stephen L. Hauser has included themes like Genome-wide association study and Oncology in his Internal medicine study. His Ocrelizumab study combines topics from a wide range of disciplines, such as Gastroenterology, Placebo, Randomized controlled trial and Interferon beta-1a. The Immunology study combines topics in areas such as Central nervous system, Allele and Risk factor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Harrison's Principles of Internal Medicine
edotir's Eugene Braunwald....
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L. Hauser;Emmanuelle Waubant;Douglas L. Arnold;Timothy Vollmer.
The New England Journal of Medicine (2008)
Risk alleles for multiple sclerosis identified by a genomewide study.
David A. Hafler;Alastair Compston;Stephen Sawcer;Mark J. Daly.
The New England Journal of Medicine (2007)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold.
The New England Journal of Medicine (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni.
The New England Journal of Medicine (2017)
Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
Walter J. Curran;Rebecca Paulus;Corey J. Langer;Ritsuko Komaki.
Journal of the National Cancer Institute (2011)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Ashley H. Beecham;Nikolaos A. Patsopoulos;Nikolaos A. Patsopoulos;Dionysia K. Xifara;Mary F. Davis.
Nature Genetics (2013)
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Claude P. Genain;Barbara Cannella;Stephen L. Hauser;Cedric S. Raine.
Nature Medicine (1999)
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Hauser Sl;Dawson Dm;Lehrich;Beal Mf.
The New England Journal of Medicine (1983)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: